- Home
- WLAC vs MEIP Comparison
WLAC vs MEIP Comparison
Compare WLAC & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLAC
- MEIP
- Stock Information
- Founded
- WLAC 2024
- MEIP 2000
- Country
- WLAC United States
- MEIP United States
- Employees
- WLAC N/A
- MEIP N/A
- Industry
- WLAC
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- WLAC
- MEIP Health Care
- Exchange
- WLAC Nasdaq
- MEIP Nasdaq
- Market Cap
- WLAC 172.6M
- MEIP 153.9M
- IPO Year
- WLAC 2024
- MEIP 2003
- Fundamental
- Price
- WLAC $10.30
- MEIP $3.17
- Analyst Decision
- WLAC
- MEIP
- Analyst Count
- WLAC 0
- MEIP 0
- Target Price
- WLAC N/A
- MEIP N/A
- AVG Volume (30 Days)
- WLAC 13.3K
- MEIP 1.2M
- Earning Date
- WLAC 01-01-0001
- MEIP 09-23-2025
- Dividend Yield
- WLAC N/A
- MEIP N/A
- EPS Growth
- WLAC N/A
- MEIP N/A
- EPS
- WLAC N/A
- MEIP N/A
- Revenue
- WLAC N/A
- MEIP N/A
- Revenue This Year
- WLAC N/A
- MEIP N/A
- Revenue Next Year
- WLAC N/A
- MEIP N/A
- P/E Ratio
- WLAC $734.67
- MEIP N/A
- Revenue Growth
- WLAC N/A
- MEIP 33.76
- 52 Week Low
- WLAC $9.80
- MEIP $1.46
- 52 Week High
- WLAC $10.60
- MEIP $9.00
- Technical
- Relative Strength Index (RSI)
- WLAC N/A
- MEIP 32.68
- Support Level
- WLAC N/A
- MEIP $2.76
- Resistance Level
- WLAC N/A
- MEIP $3.25
- Average True Range (ATR)
- WLAC 0.00
- MEIP 0.40
- MACD
- WLAC 0.00
- MEIP -0.24
- Stochastic Oscillator
- WLAC 0.00
- MEIP 14.96
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.